Adams Kendra reported tax withholding involving 2,775 shares of C4 Therapeutics, Inc. at $3.39 for −$9.41k on Sep 18, 2026

Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
Chief Financial Officer
Chief Financial Officer
Filed Sep 21, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$9,407.25Shares × reported price
Shares traded
2,775Common Stock
Price per share
$3.39Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
382,323Direct
Trade date
Sep 18, 2026Tax withholding
Filed
Sep 21, 2026, 4:24 PM ET3-day reporting delay
Accession
0001470831-26-000895Code F · Transaction 226655
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 18, 2026Option exercise6,250$0.00$0Trade 226654
2 transaction rows in this filing. Joint filers share the same rows.

CCCC price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CCCC · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +1.7%1w ago 0%1d ago 0%
Returns since7d −25%30d −23%90d180d1y

Footnotes in full

F1: Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on September 19, 2023. F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.